

Sub
B3
A2

13. (Once amended) A method for the treatment or prevention of Alzheimer's disease, in a human, comprising administering to [a] the human in need thereof and effective amount of an agent which [results in lowered serum insulin levels] increases the insulin sensitivity of the human and restricting the metabolizable carbohydrates in the diet of the human.

RECEIVED

APR 14 2000

TECH CENTER 1600/2900

Please add the following new claims:

Sub
B3
A2

--21. The method of claim 6, wherein said thiazolidinedione is 5-[4-[2-(5-ethylpyridin-2-yl)ethoxyl]benzyl]thiadiazolidine-2,4-dione.

A3

22. The method of claim 6, wherein said thiazolidinedione is 5-[4-[2-(5-ethylpyridin-2-yl)ethoxyl]benzyl]thiadiazolidine-2,4-dione hydrochloride.

23. The method of claim 6, wherein said thiazolidinedione is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiadiazolidine-2,4-dione.

24. The method of claim 6, wherein said thiazolidinedione is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiadiazolidine-2,4-dione maleate.--

Remarks

Upon entry of the foregoing amendment, claims 1-8 and 13-24 are pending in the application, with claims 1, 8, 13 and 20 being the independent claims. Claims 9-12 are